Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

607 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Somatic variant profiling in chronic phase pediatric chronic myeloid leukemia.
Behrens YL, Gaschler L, Nienhold R, Reinkens T, Schirmer E, Knöß S, Strasser R, Sembill S, Wotschofsky Z, Suttorp M, Krumbholz M, Schlegelberger B, Metzler M, Göhring G, Karow A. Behrens YL, et al. Among authors: metzler m. Haematologica. 2024 Mar 1;109(3):942-947. doi: 10.3324/haematol.2023.283800. Haematologica. 2024. PMID: 37706343 Free PMC article. No abstract available.
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
Häselbarth L, Karow A, Mentz K, Böttcher M, Roche-Lancaster O, Krumbholz M, Jitschin R, Mougiakakos D, Metzler M. Häselbarth L, et al. Among authors: metzler m. Cancer Immunol Immunother. 2023 Jun;72(6):1661-1672. doi: 10.1007/s00262-022-03361-8. Epub 2023 Jan 5. Cancer Immunol Immunother. 2023. PMID: 36602564 Free PMC article.
Synergistic lethality in chronic myeloid leukemia - targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment.
Häselbarth L, Gamali S, Saul D, Krumbholz M, Böttcher-Loschinski R, Böttcher M, Zou D, Metzler M, Karow A, Mougiakakos D. Häselbarth L, et al. Among authors: metzler m. BMC Cancer. 2023 Nov 27;23(1):1153. doi: 10.1186/s12885-023-11623-6. BMC Cancer. 2023. PMID: 38012567 Free PMC article.
Imatinib treatment and longitudinal growth in pediatric patients with chronic myeloid leukemia: Influence of demographic, pharmacological, and genetic factors in the German CML-PAED cohort.
Stiehler S, Sembill S, Schleicher O, Marx M, Rauh M, Krumbholz M, Karow A, Suttorp M, Woelfle J, Maj C, Metzler M. Stiehler S, et al. Among authors: metzler m. Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284668. Online ahead of print. Haematologica. 2024. PMID: 38497150 Free article.
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukaemia in children and young adults.
Feuchtinger T, Bader P, Subklewe M, Breidenbach M, Willier S, Metzler M, Gökbuget N, Hauer J, Müller F, Schlegel PG, Frühwald M, Schmid C, Troeger A, Baldus C, Meisel R, Künkele A, Topp M, Bourquin JP, Cario G, Von Stackelberg A, Peters C. Feuchtinger T, et al. Among authors: metzler m. Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.283780. Online ahead of print. Haematologica. 2024. PMID: 38356450 Free article.
607 results